Lipoxin A4 induces hyperadhesiveness in human endothelial cells for neutrophils.
Lipoxin A4 (LXA4), but not lipoxin B4, induced in vitro a dose-dependent, slowly emerging hyperadhesiveness in human umbilical vein endothelial cells (HUVEC), leading to a 1.9-fold increase in the binding of neutrophils (polymorphonuclear neutrophil granulocytes [PMN]). The maximal response to LXA4 occurred at 1 nmol/L and after 30 minutes of treatment of HUVEC. These response kinetics were intermediate in comparison with those of fast-acting inducers of HUVEC adhesivity (eg, thrombin, leukotriene B4 [LTB4] or platelet activating factor [PAF]), needing 5 to 15 minutes, or to the slow inducer interleukin-1 (IL-1 beta), which requires hours. The maximal LXA4 effect was slightly lower than that of LTB4 (100 nmol/L) and thrombin (1 U/mL), and less than that of PAF (100 nmol/L) or IL-1 beta (2.5 U/mL) (2.2-, 2.0-, 2.4-, or 13.6-fold increases, respectively). The LXA4 effect was inhibited by the PAF receptor antagonist WEB-2086; however, it could not be blocked by pertussis toxin. LXA4 conferred a slow, sustained increase in HUVEC cytosolic calcium ion concentrations, whereas thrombin did so rapidly and transiently. LXA4 also caused PMN to become hyperadhesive. Thus, this novel effect of LXA4 on HUVEC appears to be associated with endogenous PAF expression and slow increases of cytosolic calcium concentrations but not pertussis-sensitive G proteins.
Lerner
R
R
Department of Medicine, Karolinska Institute, Stockholm Söder Hospital, Sweden.
Heimburger
M
M
Palmblad
J
J
D002118:Calcium / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000166:cytology*; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000494:pharmacology*; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000494:pharmacology; D007975:Leukotriene B4 / Q000494:pharmacology; D044045:Lipoxins; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000166:cytology*; D010972:Platelet Activating Factor / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology
D006893:Hydroxyeicosatetraenoic Acids; D007375:Interleukin-1; D044045:Lipoxins; D010972:Platelet Activating Factor; C040527:lipoxin A4; D007975:Leukotriene B4; D009240:N-Formylmethionine Leucyl-Phenylalanine; C042651:lipoxin B4; D013917:Thrombin; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium